Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $62.25 Average PT from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $62.25.

A number of research analysts have issued reports on CLDX shares. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 16th. Citigroup initiated coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, September 26th.

Celldex Therapeutics Stock Down 1.7 %

Shares of Celldex Therapeutics stock opened at $28.25 on Monday. Celldex Therapeutics has a 12 month low of $22.11 and a 12 month high of $53.18. The business has a fifty day simple moving average of $36.33 and a 200 day simple moving average of $37.07.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The business had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. As a group, equities research analysts expect that Celldex Therapeutics will post -2.5 EPS for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Celldex Therapeutics during the second quarter worth about $76,000. Headlands Technologies LLC bought a new stake in Celldex Therapeutics in the first quarter valued at approximately $147,000. CANADA LIFE ASSURANCE Co raised its stake in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 955 shares during the period. Ameritas Investment Partners Inc. raised its stake in Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 1,582 shares during the period. Finally, Los Angeles Capital Management LLC bought a new stake in Celldex Therapeutics in the first quarter valued at approximately $283,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.